<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04136223</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-839</org_study_id>
    <nct_id>NCT04136223</nct_id>
  </id_info>
  <brief_title>Rheumatoid Arthritis-Associated Interstitial Lung Disease: Characterization of Lung Disease Progression</brief_title>
  <acronym>BERTHA</acronym>
  <official_title>BERTHA Study: Rheumatoid Arthritis-Associated Interstitial Lung Disease: Characterization of Lung Disease Progression. A Multicenter, Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital do Coracao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>DASA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital do Coracao</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BERTHA study´s primary objective is to characterize Rheumatoid Arthritis-associated
      Interstitial Lung Disease (RA-ILD) progression and to define a combination of protein
      biomarkers, genetic and clinical variables capable of identifying pts at risk of RA-ILD
      progression
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BERTHA is a multicentric, observational study that will enroll 100 RA-ILD patients to be
      followed for 2 years.

      Interstitial Lung Disease (ILD) progression will be ascertained by quantitative image
      analysis and functional parameters. Variables associated with progression, including blood
      protein biomarkers and genetic variables, with be identified.

      Additionally, sub-phenotypes of RA-ILD will be investigated as well as their association with
      RA-ILD progression.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Interstitial Lung Disease progression - continuous variable</measure>
    <time_frame>2 years</time_frame>
    <description>Quantitative analysis of the %ILD extent and % Vessel Related Structures (VRS) on the high-resolution computed tomography (HRCT) of the Chest</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interstitial Lung Disease progression - death</measure>
    <time_frame>2 years</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interstitial Lung Disease progression - dichotomous variables</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of patients with a change from baseline in the % vessel related structures (VSR) &gt; 4.4% on the HRCT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interstitial Lung Disease progression - dichotomous variables</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of patients with a change from baseline in the %Forced Vital Capacity (FVC) greater or equal to 10%</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Rheumatoid Lung</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Interstitial Lung Disease</condition>
  <condition>Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>RA-ILD</arm_group_label>
    <description>Consecutive adult patients (aged &gt;18 years) with RA* and interstitial lung disease
*in accordance with the American College of Rheumatology (ACR) classification criteria of 2010</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        RA-ILD patients defined by altered imaging and associated functional derangements and/ or
        symptoms
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Consecutive adult patients (aged &gt;18 years) meeting RA diagnostic criteria in
             accordance with ACR 2010

          2. Presence of interstitial lung disease 2.1 ILD Definition: presence of interstitial
             alterations in HRCT associated to functional derangements and/or symptoms

          3. Patient agrees with having follow-up visits every 6 months for 2 years

        Exclusion Criteria:

          1. Pregnancy or intending to become pregnant

          2. Overlap with other diseases that occurs with ILD (other collagenoses, vasculitis,
             inflammatory bowel disease)

          3. Presence of advanced ILD, characterized by:

               1. Dyspnea rated as modified Medical Research Council 4 (mMRC4) on routine visit, or

               2. FVC&lt;50% prediction or

               3. Carbon Monoxide diffusion (DLCO) &lt;40% prediction

          4. Presence of significant Arterial Pulmonary Hypertension:

               1. Evidence of Right ventricular failure evidence by echocardiography

               2. Previous right chamber catheterism showing cardiac index &lt; 2 liters/min/m²

          5. Significant co-morbidity impacting respiratory system (e.g., congestive heart failure,
             lung neoplasm)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leticia Kawano Dourado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital do Coração</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leticia Kawano Dourado, MD</last_name>
    <phone>+55 11 3053-6611</phone>
    <phone_ext>8209</phone_ext>
    <email>ldourado@hcor.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Priscila Bueno, BA/BS</last_name>
    <phone>+55 11 3053-6611</phone>
    <phone_ext>8209</phone_ext>
    <email>pbueno@hcor.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Regional de Sobradinho</name>
      <address>
        <city>Brasília</city>
        <state>DF</state>
        <zip>70297-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Luciana Muniz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luciana Muniz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário de Brasilia (HUB)</name>
      <address>
        <city>Brasília</city>
        <state>DF</state>
        <zip>70840-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Licia Mota, MD</last_name>
    </contact>
    <investigator>
      <last_name>Licia Mota, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Estadual de Campinas (UNICAMP)</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13083-872</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Alisson Pugliesi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alisson Pugliesi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas - FMUSP</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Karina Bonfiglioli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Karina Bonfiglioli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 21, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>October 22, 2019</last_update_submitted>
  <last_update_submitted_qc>October 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Under development</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

